India, Nov. 18 -- Teva Pharmaceuticals Industries (TEVA) announced that Dr. Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer, will leave the company after accepting a position outside Teva.
Hughes will remain with the company during the coming months to support a leadership transition while Teva conducts a search for permanent successor.
Effective immediately, Dr. David Gardiner, Head of Innovative Medicines & Clinical Development, will serve as interim R&D transition lead and report directly to CEO Richard Francis.
The company emphasized that its "Pivot to Growth" strategy, research priorities and financial objectives remain unchanged, including its goal of generating $6 billion to $7 billion in innovative med...